Patritumab deruxtecan demonstrates antitumor activity in pat

Patritumab deruxtecan induced a 39% overall response rate among patients with advanced, EGFR-mutant non-small cell lung cancer, according to phase 1 study results presented during the virtual ASCO Annual Meeting.
“EGFR inhibitors are the standard of care for patients with advanced EGFR-mutant NSCLC. However, resistance inevitably develops, and the mechanisms of resistance are diverse. As

Related Keywords

Daiichi Sankyo , Jennifer Southall , Astrazeneca , Dana Farber Cancer Institute , Harvard Medical School , தய்ச்சி சாங்கியோ , ஜெனிபர் தென்கிழக்கு , டானா ஃபார்‌பர் புற்றுநோய் நிறுவனம் , ஹார்வர்ட் மருத்துவ பள்ளி ,